Literature DB >> 10228994

Influence of alpha-tocopherol over the time course of experimental IgA nephropathy.

N B Kuemmerle1, R J Krieg, W Chan, H Trachtman, E P Norkus, J C Chan.   

Abstract

The present study investigated the pathogenesis and the time course of kidney injury in experimental IgA nephropathy. In order to determine an appropriate period in the course of experimental IgA nephropathy to study renal injury and repair, we examined proteinuria and IgA deposition in the renal mesangium after 4, 8, and 16 weeks of mucosal challenge by bovine gamma globulins (BGG) provided in the drinking water. The hallmark of IgA deposition in the mesangium was present after 4 weeks and 8 weeks of BGG inoculation, but by 16 weeks, the mesangial IgA deposition had resolved. In addition, we confirmed our previous report on the beneficial effects of alpha-tocopherol in reducing proteinuria in IgA nephropathy at 8 weeks, and extended this observation to investigate the effects of dietary supplementation of alpha-tocopherol at both 4 weeks and 16 weeks. Proteinuria resolved spontaneously at 16 weeks. There is oxidative stress, as suggested by the elevation in plasma and renal malondialdehyde content, and increased fibrogenic cytokine message, as suggested by elevated transforming growth factor beta1 mRNA. These increases were clearly blunted by alpha-tocopherol at both 4 weeks and 8 weeks. Treatment with alpha-tocopherol was associated with a significant reduction in the severity of proteinuria. Thus, our data suggest that the period between 4 and 8 weeks of BGG vaccination could be relevant in designing an appropriate model to study the molecular biology of the pathogenesis of renal injury and the effects of treatment. The 16-week model may be useful in exploring gene expression involved with spontaneous resolution.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228994     DOI: 10.1007/s004670050573

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  5 in total

1.  Progression of IgA nephropathy under current therapy regimen in a Chinese population.

Authors:  Xiangling Li; Youxia Liu; Jicheng Lv; Sufang Shi; Lijun Liu; Yuqing Chen; Hong Zhang
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

2.  Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.

Authors:  Kar Neng Lai; Loretta Y Y Chan; Hong Guo; Sydney C W Tang; Joseph C K Leung
Journal:  Pediatr Nephrol       Date:  2010-12-02       Impact factor: 3.714

Review 3.  Vitamin E in renal therapeutic regiments.

Authors:  Mohamed Alaa Thabet; James C M Chan
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

4.  Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study.

Authors:  James C M Chan; John D Mahan; Howard Trachtman; Jon Scheinman; Joseph T Flynn; Uri S Alon; Marc B Lande; Robert A Weiss; Edward P Norkus
Journal:  Pediatr Nephrol       Date:  2003-08-12       Impact factor: 3.714

5.  Toll-like Receptor 4 Signaling Pathway in the Protective Effect of Pioglitazone on Experimental Immunoglobulin A Nephropathy.

Authors:  Jia-Nan Zou; Jing Xiao; Sha-Sha Hu; Chen-Sheng Fu; Xiao-Li Zhang; Zhen-Xing Zhang; Yi-Jun Lu; Wei-Jun Chen; Zhi-Bin Ye
Journal:  Chin Med J (Engl)       Date:  2017-04-20       Impact factor: 2.628

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.